Additionally, the trial will evaluate its effects on atherosclerotic risk factors, such as LDL-c, HbA1c levels, and high-sensitivity C-reactive protein [82]
Nishimura M, Ohkawara T, Kanayama T, Kitagawa K, Nishimura H, Nishihira J
*Correspondence: Gaosi Xu, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Du J, Zhang M, Lu J et al (2016) Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK